1461047909-1ca0f40f-0251-4281-a766-27847a14edd3

1) An aluminum alloy product comprising:
a first outer layer;
a central layer; and
a second outer layer;
wherein central layer having a higher concentration of particulate matter than said first or second outer layers, the particular matter has a size of at least about 30 microns, and the aluminum alloy product has a thickness ranging from between about 0.004 inches to about 0.25 inches.
2) The aluminum alloy product of claim 1, wherein the particulate matter is selected from the group consisting of aluminum oxide; boron carbide; silicon carbide; boron nitride; and any non-metallic material.
3) The aluminum alloy product of claim 1, wherein a volume of the central layer has up to about 70 volume percent aluminum oxide particles.
4) The aluminum alloy product of claim 1, wherein, the aluminum alloy product is fabricated using a strip casting process.
5) The aluminum alloy product of claim 1, wherein the aluminum alloy product is selected from the group consisting of a single-cast aluminum alloy strip, a single-cast aluminum alloy sheet, a single-cast aluminum alloy panel, a single-cast aluminum alloy slab, a single-cast aluminum alloy foil, a single-cast aluminum alloy wire, a single-cast aluminum alloy rod, and a single-cast aluminum alloy bar.
6) The aluminum alloy product of claim 1, wherein the aluminum alloy product has a thickness ranging from about 0.08 inches to about 0.25 inches.
7) The aluminum alloy product of claim 1, wherein about 70%, by volume, of the particulate matter is in the central layer, about 10%, by volume, of the particulate matter is in the first outer layer, and about 10%, by volume, of the particulate matter is in the second outer layer.
8) An aluminum alloy product comprising:
a first shell;
a second shell; and
a central layer disposed between the first shell and the second shell;
wherein particulate matter is distributed across the first shell, the central layer, and the second shell in a concentration gradient;
wherein the central layer has a higher concentration of particulate matter than the first shell and the second shell;
wherein the particulate matter is selected from the group consisting of aluminum oxide, boron carbide, silicon carbide, boron nitride and any non-metallic material;
wherein the particulate matter has a size of at least about 30 microns;
wherein the aluminum alloy product has a thickness ranging from between about 0.004 inches to about 0.25 inches; and
wherein the aluminum alloy product is selected from the group consisting of a single-cast aluminum alloy strip, a single-cast aluminum alloy sheet, a single-cast aluminum alloy panel, a single-cast aluminum alloy slab, a single-cast aluminum alloy foil, a single-cast aluminum alloy wire, a single-cast aluminum alloy rod, and a single-cast aluminum alloy bar.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of Formula I and its pharmaceutically acceptable acid addition salts or hydrates thereof
19
wherein
R1 and R4 are independently selected from lower alkyl and CO2R6 where R6 is lower alkyl;
R2 and R3 are independently selected from lower alkyl;
R5 is hydrogen or halogen;
n is an integer selected from 1 to 5;
Z is
20
or
21
where X is CH or N;
R7 and R8 are independently selected from lower alkyl and lower alkanol, R9 is hydrogen, lower alkyl, CO2R6, (CH2)mR10, hydroxy, cyano, and (CH2)m NR11R12.;
R10 is selected from C3-7 cycloalkyl, naphthyl and
22
R13 is selected from hydrogen, lower alkyl, lower alkenyl, C3-7 cycloalkyl, lower alkoxy, hydroxy, dialkylamino, phenoxy, amino, NRCOR6, CO2R6, NO2, trifluoromethyl, and phenyl;
m is zero or an integer of 1 to 3;
R11 and R12 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkylene, phenyl, alkylamino, heterocyclic alkyl, methoxy, cyano, lower alkanol, naphthyl, furfuryl, tetrahydrofurfuryl, thiophene, azetidine, lower alkyl ethers, esters, acetamides and carbamates;
and where
23
is a heterocyclic amine or imine.
2. The compound of claim 1, wherein R1 and R2 are CO2R6.
3. The compound of claim 1, wherein n is 3.
4. The compound of claim 1, wherein R5 is F.
5. The compound of claim 1, wherein Z is 3-methoxyphenylpiperidinyl.
6. The compound of claim 1, wherein Z is 4-phenylpiperidinyl.
7. The compound of claim 1, selected from the group consisting of
1-4-dihydro-4-3-3-4-(3-methoxyphenyl)piperidinylpropylaminocarbonothioylaminophenyl-2,6-dimethyl-3,5-pyridine dicarboxylic acid, dimethyl ester,
1,4-dihydro-4-3-3-(4-phenylpiperidinyl)propylaminocarbonothioylaminophenyl-2,6-dimethyl-3,5-pyridine dicarboxylic acid, dimethyl ester, and
1,4-dihydro-4-4-3-(4-cyclohexyl-1-piperazinyl)propylaminocarbonothioylaminophenyl-2,6-dimethyl-3,5-pyridine dicarboxylic acid, dimethyl ester.
8. The compound of claim 1, selected from the group consisting of
1,4-dihydro-4-4-fluoro-3-3-(4-phenylpiperidinyl)propylaminocarbonothioylaminophenyl-2,6-dimethyl-3,5-pyridine dicarboxylic acid, dimethyl ester,
1,4-dihydro-4-3-3-(4-methyl-1-piperidinyl)propylaminocarbonothioylamino-4-fluorophenyl-2,6-dimethyl-3,5-pyridine dicarboxylic acid, dimethyl ester,
1,4-dihydro-4-3-3-(4-ethyl-1-piperidinyl)propylaminocarbonothioylamino-4-fluorophenyl-2,6-dimethyl-3,5-pyridine dicarboxylic acid, dimethyl ester,
1,4-dihydro-4-3-3-(4-propyl-1-piperidinyl)propylaminocarbonothioylamino-4-fluorophenyl-2,6-dimethyl-3,5-pyridine dicarboxylic acid, dimethyl ester,
1,4-dihydro-4-3-3-4-1,1-dimethylethyl)-1-piperidinylpropylaminocarbonothioylamino-4-fluorophenyl-2,6-dimethyl-3,5-pyridine dicarboxylic acid, dimethyl ester,
1,4-dihydro-4-3-3-4-(1-methylethyl)-1-piperidinylpropylaminocarbonothioylamino-4-fluorophenyl-2,6-dimethyl-3,5-pyridine dicarboxylic acid, dimethyl ester, and
1,4-dihydro-4-4-3-(4-cyclohexyl-1-piperazinyl)propylaminocarbonothioylamino-4-fluorophenyl-2,6-dimethyl-3,5-pyridine dicarboxylic acid, dimethyl ester.
9. A method of promoting weight loss and treating eating disorders in a mammal comprising administering to a mammalian host an anorexiant effective dose of a compound claimed in claim 1.
10. A method of treating clinical disorders amenable to alleviation by eliciting an NPY Y1 response, comprising administering to a patient suffering from such a disorder an effective amount of a compound claimed in claim 1.
11. A pharmaceutical composition for use in promoting weight loss and treating eating disorders, the composition comprising an anorexiant effective amount of a compound claimed in claim 1 in combination with a pharmaceutically acceptable carrier.